Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Prevalence and profile of potential drug-drug interactions in hospitalized pediatric patients: A cross-sectional study
Prevalencia y perfil de posibles interacciones fármaco-fármaco en pacientes pediátricos hospitalizados: un estudio transversal
Prevalência e perfil de potenciais interações medicamentosas em pacientes pediátricos hospitalizados: um estudo transversal
DOI:
https://doi.org/10.15446/rcciquifa.v55n2.124322Palabras clave:
Drug interactions, polypharmacy, pediatrics, inpatients, cross-sectional studies (en)Interacciones de medicamentos, polifarmacia, pediatría, pacientes internos, estudios transversales (es)
Interações medicamentosas, polifarmácia, pediatria, pacientes internados, estudos transversais (pt)
Descargas
Background: Knowledge regarding the actual frequency of potential drug-drug interactions (DDIs) in pediatric settings remains limited. The aim of this study was to characterize the prevalence and profile of potential DDIs in pediatric patients at two high-complexity hospitals. Methods: A descriptive cross-sectional study was conducted among 470 pediatric patients hospitalized between July and December 2022. Data were extracted from prescription databases, and the theoretical severity of interactions was assessed using Drugs.com® and DrugBank®. Results: The study revealed an overall prevalence of potential DDIs of 57.4% (95% CI, 52.9–61.8%). Regarding clinical relevance, 2.7% were classified as major, 27.6% as moderate, and 42.5% as minor. The therapeutic classes most frequently involved in interactions were analgesics, systemic corticosteroids, and antimicrobials. Conclusions: A high prevalence of potential DDIs was identified, primarily associated with the simultaneous use of multiple medications. These findings underscore the critical need to strengthen systematic treatment reviews and implement clinical decision-support tools for prescribing in hospital practice.
Antecedentes: El conocimiento sobre la frecuencia real de las interacciones medicamentosas potenciales (IMP) en el entorno pediátrico sigue siendo limitado. El objetivo de este estudio fue caracterizar la prevalencia y el perfil de las IMP en pacientes pediátricos de dos hospitales de alta complejidad. Métodos: Se realizó un estudio descriptivo de corte transversal en 470 pacientes pediátricos hospitalizados entre julio y diciembre de 2022. Los datos se extrajeron de las bases de datos de prescripción y la gravedad teórica de las interacciones se evaluó mediante Drugs.com® y DrugBank®. Resultados: Se observó una prevalencia global de IMP del 57,4% (IC 95%: 52,9–61,8%). Respecto a la relevancia clínica, el 2,7% fueron clasificadas como mayores, el 27,6% como moderadas y el 42,5% como menores. Los grupos terapéuticos involucrados con mayor frecuencia fueron analgésicos, corticosteroides sistémicos y antimicrobianos. Conclusiones: Se identificó una alta prevalencia de IMP, asociada principalmente al uso simultáneo de múltiples medicamentos. Estos hallazgos subrayan la necesidad crítica de fortalecer la revisión sistemática de los tratamientos y la implementación de herramientas de apoyo a la decisión clínica en la práctica hospitalaria.
Contexto: O conhecimento sobre a frequência real de potenciais interações medicamentosas (PIMs) no contexto pediátrico ainda é limitado. O objetivo deste estudo foi caracterizar a prevalência e o perfil de PIMs em pacientes pediátricos em dois hospitais de alta complexidade. Métodos: Foi realizado um estudo descritivo transversal com 470 pacientes pediátricos hospitalizados entre julho e dezembro de 2022. Os dados foram extraídos de bancos de dados de prescrições e a gravidade teórica das interações foi avaliada utilizando o Drugs.com® e o DrugBank®. Resultados: Observou-se uma prevalência geral de PIMs de 57,4% (IC 95%: 52,9–61,8%). Em relação à relevância clínica, 2,7% foram classificadas como graves, 27,6% como moderadas e 42,5% como leves. Os grupos terapêuticos mais frequentemente envolvidos foram analgésicos, corticosteroides sistêmicos e antimicrobianos. Conclusões: Foi identificada uma alta prevalência de interações medicamentosas, principalmente associadas ao uso concomitante de múltiplos medicamentos. Esses achados reforçam a necessidade crucial de fortalecer as revisões sistemáticas de tratamentos e a implementação de ferramentas de apoio à decisão clínica na prática hospitalar.
Referencias
1. J. Niu, R.M. Straubinger & D.E. Mager. Pharmacodynamic drug-drug interactions. Clinical Pharmacology & Therapeutics, 105(6), 1395–1406 (2019). https://doi.org/10.1002/cpt.1434
2. K.A. Pruskowski. Pharmacokinetics and pharmacodynamics of antimicrobial agents in burn patients. Surgical Infections (Larchmt), 22(1), 77–82 (2021). https://doi.org/10.1089/sur.2020.375
3. N. Murray. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Journal of Pharmacy and Pharmacology, 58(7), 871–885 (2006). https://doi.org/10.1211/jpp.58.7.0001
4. A. Douros, K. Grabowski & R. Stahlmann. Safety issues and drug-drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism & Toxicology, 11(1), 25–39 (2015). https://doi.org/10.1517/17425255.2014.970166
5. P.D. Hansten. Drug interaction management. Pharmacy World and Science, 25, 94–97 (2003). https://doi.org/10.1023/a:1024077018902
6. B. Percha & R.B. Altman. Informatics confronts drug-drug interactions. Trends in Pharmacological Sciences, 34(3), 178–184 (2013). https://doi.org/10.1016/j.tips.2013.01.006
7. L. Magro, U. Moretti & R. Leone. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opinion on Drug Safety, 11(1), 83–94 (2012). https://doi.org/10.1517/14740338.2012.631910
8. K.A. Oshikoya, I.A. Oreagba, S. Lawal, O. Awodele, O.O. Ogunleye, I.O. Senbanjo, et al. Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria. HIV/AIDS: Research and Palliative Care, 2014, 49–59 (2014). https://doi.org/10.2147/hiv.s52266
9. D. Dai, J.A. Feinstein, W. Morrison, A.F. Zuppa & C. Feudtner. Epidemiology of polypharmacy and potential drug–drug interactions among pediatric patients in intensive care units of U.S. children's hospitals. Pediatric Critical Care Medicine, 17(5), e218–e228 (2016). https://doi.org/10.1097/pcc.0000000000000684
10. S.C. Dharmage, J.L. Perret & A. Custovic. Epidemiology of asthma in children and adults. Frontiers in Pediatrics, 7, 246 (2019). https://doi.org/10.3389/fped.2019.00246
11. K.E. Lafond, H. Nair, M.H. Rasooly, F. Valente, R. Booy, M. Rahman, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: A systematic analysis. PLoS Medicine, 13(3), e1001977 (2016). https://doi.org/10.1371/journal.pmed.1001977
12. K.E. Kyler, M. Hall, J.W. Antoon, J. Goldman, S.S. Shah, S. Tang-Girdwood, D.J. Williams & J.A. Feinstein. Major drug-drug interaction exposure among Medicaid-insured children in the outpatient setting. Pediatrics, 153(2), e2023063506 (2024). https://doi.org/10.1542/peds.2023-063506
13. J.M. Mirtallo. Complications associated with drug and nutrient interactions. Journal of Infusion Nursing, 27(1), 19–24 (2004). https://doi.org/10.1097/00129804-200401000-00003
14. B. Arora & N. Kannikeswaran. The serotonin syndrome—the need for physician’s awareness. International Journal of Emergency Medicine, 3, 373–377 (2010). https://doi.org/10.1007/s12245-010-0195-7
15. A.E. Horace & F. Ahmed. Polypharmacy in pediatric patients and opportunities for pharmacists' involvement. Integrated Pharmacy Research and Practice, 2015, 113–126 (2015). https://doi.org/10.2147/iprp.s64535
16. T.d.S. Alcântara, F.C. de Araújo-Neto, H. Ferreira-Lima, D.C.S. Anacleto de Araújo, J. Mirão-Sanchez, G.T. Aires-Moreno, C. de Carvalho-Silvestre & D.P. de Lyra-Junior. Prevalence of medication discrepancies in pediatric patients transferred between hospital wards. International Journal of Clinical Pharmacy, 43(4), 909–917 (2021). https://doi.org/10.1007/s11096-020-01196-w
17. C. Santibáñez, J. Roque, G. Morales & R. Corrales. Características de las interacciones farmacológicas en una unidad de cuidados intensivos de pediatría. Revista Chilena de Pediatría, 85(5), 546–553 (2014). https://doi.org/10.4067/s0370-41062014000500004
18. M. Zitnik, M. Agrawal & J. Leskovec. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13), i457–i466 (2018). https://doi.org/10.1093/bioinformatics/bty294
19. J.A. Ross & D.L. Eldridge. Pediatric toxicology. Emergency Medicine Clinics of North America, 40(2), 237–250 (2022). https://doi.org/10.1016/j.emc.2022.01.004
20. E. Vázquez-Cornejo, S.I. Román-García & O. Morales-Ríos. Prevalencia y tipos de interacciones farmacológicas en pacientes pediátricos hospitalizados en la Ciudad de México. Farmacia Hospitalaria, 45(5), 234–239 (2021). https://doi.org/10.7399/fh.11633
21. A. Sheikh, J. Coleman, A. Chuter, R. Williams, R. Lilford, A. Slee, et al. Electronic prescribing systems in hospitals to improve medication safety: A multimethods research programme. Programme Grants for Applied Research, 10(7), 196 p (2022). https://doi.org/10.3310/ksrs2009. URL: https://www.ncbi.nlm.nih.gov/books/NBK584773/pdf/Bookshelf_NBK584773.pdf
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Derechos de autor 2026 Revista Colombiana de Ciencias Químico-Farmacéuticas
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13
